8-K: Kineta Completes Enrollment in Monotherapy Arm of VISTA-101 Clinical Trial, Advances Combination Study

Kineta has completed enrollment in the monotherapy arm of its Phase 1 VISTA-101 clinical trial for advanced solid tumors and is progressing with combination therapy studies.

Summary

• Kineta, a clinical-stage biotechnology company, has finished enrolling patients in the monotherapy arm of its Phase 1 VISTA-101 clinical trial.
• The trial is evaluating KVA12123, a novel VISTA blocking immunotherapy, in patients with advanced solid tumors.
• The monotherapy portion of the trial included six dose cohorts ranging from 3mg to 1000mg every two weeks.
• No dose-limiting toxicities or cytokine-related adverse events were observed in the monotherapy study.
• Kineta is now enrolling patients in cohorts evaluating KVA12123 in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab).
• Initial results from the combination therapy showed partial response and stable disease, while monotherapy cohorts showed durable stable disease.
• These initial results were presented at the American Association of Cancer Research (AACR) Annual Meeting 2024.
• KVA12123 has demonstrated a favorable clinical safety and tolerability profile with no dose-limiting toxicities or evidence of CRS-associated cytokines at any dose level.
• Kineta received a $5 million nonrefundable payment from TuHURA Biosciences in July 2024 as part of an exclusivity and right of first offer agreement.
• TuHURA has exercised its right to extend their exclusivity and right of first offer agreement with Kineta.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the completion of enrollment in the monotherapy arm, the progress in combination therapy, and the favorable safety profile of KVA12123. The collaboration with TuHURA and the $5 million payment also contribute to the positive outlook. However, the previous restructuring and the inherent risks of clinical trials temper the overall sentiment.

Positives

• The completion of enrollment in the monotherapy arm of the VISTA-101 trial is a positive milestone.
• The absence of dose-limiting toxicities and cytokine-related adverse events in the monotherapy study is encouraging.
• The progress into combination therapy trials with KEYTRUDA is a positive step.
• Initial results showing partial response and stable disease in combination therapy are promising.
• The $5 million nonrefundable payment from TuHURA provides financial support.
• The extension of the exclusivity agreement with TuHURA indicates continued collaboration and potential future opportunities.

Negatives

• The document does not explicitly state any negative results, but the company did undergo a significant corporate restructuring in February 2024 to reduce expenses and preserve cash, including a workforce reduction and suspension of enrollment in the VISTA-101 trial, which could be seen as a negative.

Risks

• The company faces risks associated with clinical trial success, including the time and cost of development.
• There are risks related to the timing and results of pre-clinical and clinical trials.
• The company is subject to risks related to regulatory approvals and market acceptance of its product candidates.
• There are risks associated with the volatility and uncertainty in the capital markets for biotechnology companies.
• The company's ability to fund its operations and capital requirements is a risk.
• The company faces risks related to its ability to protect its intellectual property.

Future Outlook

Kineta is continuing to enroll patients in the combination therapy arm of the VISTA-101 trial and expects to present additional scientific data in 2024 at an upcoming scientific meeting. The company remains on target for completing full enrollment into this study before year end.

Management Comments

• We are pleased to successfully complete patient enrollment in the monotherapy arm, and we remain on target for completing full enrollment into this study before year end, said Craig W. Philips, President of Kineta.

Industry Context

The announcement is relevant to the immuno-oncology field, where companies are developing novel therapies to address cancer immune resistance. The combination therapy approach with KEYTRUDA is a common strategy in the industry.

Comparison to Industry Standards

• The use of anti-PD-1 therapies like KEYTRUDA in combination with other immunotherapies is a common approach in the industry, with companies like Bristol Myers Squibb (Opdivo) and Roche (Tecentriq) also pursuing similar strategies.
• The reported safety profile of KVA12123, with no dose-limiting toxicities or CRS-associated cytokines, is a positive sign, as these are common concerns in immunotherapy development.
• The reported partial response and stable disease in the combination therapy arm is consistent with early-stage clinical trial results for similar therapies.
• The collaboration with TuHURA is similar to other partnerships in the biotech industry, where companies combine resources and expertise to accelerate drug development.

Related Party Transactions

• Kineta entered into an exclusivity and right of first offer agreement with TuHURA Biosciences, which included a $5 million nonrefundable payment.

Stakeholder Impact

• Shareholders may view the clinical trial progress and collaboration with TuHURA positively.
• Employees may be impacted by the company's restructuring and future strategic decisions.
• Patients with advanced solid tumors may benefit from the development of new immunotherapies.
• The company's suppliers and creditors may be affected by its financial performance and strategic direction.

Next Steps

• Kineta will continue to enroll patients in the combination therapy arm of the VISTA-101 trial.
• The company will present additional scientific data in 2024 at an upcoming scientific meeting.
• Kineta aims to complete full enrollment into the study before year end.

Key Dates

Keywords

KVA12123, VISTA-101, immunotherapy, clinical trial, oncology, solid tumors, KEYTRUDA, pembrolizumab, TuHURA Biosciences, monotherapy, combination therapy